News

Video

Fatigue or Autoimmune Disease? Physician Talks Immunotherapy Side Effects

Author(s):

Yvonne Saenger, MD

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team.

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team at the Society for Immunotherapy of Cancer (SITC) 101 session.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.
Related Content
Image of kelly.
May 23rd 2025

Ovarian Cancer Treatment Side Effects Make for a Difficult Balancing Act

Kelly Irvin
I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact their efficacy.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma: © stock.adobe.com.
May 19th 2025

First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma

Spencer Feldman
The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
ASHLEY TULLIO, B.S.N., RN
May 6th 2025

Fighting for Patients, Processes and Education

Dr. Theresa Medina
I would like to nominate Ashley Tullio, RN, for the Extraordinary Healer Award for Oncology Nursing.